Chronic Smell and Flavor Loss Treatment Market Report 2025

The chronic smell and flavor loss treatment market size has grown strongly in recent years. It will grow from $2.45 billion in 2024 to $2.64 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to increasing demand for post-viral olfactory dysfunction treatments, rising adoption of smell training therapies, growing use of corticosteroid-based interventions, increasing ENT consultations for sensory loss, and expanding clinical trials focused on anosmia.

The chronic smell and flavor loss treatment market size is expected to see strong growth in the next few years. It will grow to $3.56 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to increasing use of regenerative medicine approaches, rising adoption of gene-based therapies, growing investment in biotech startups targeting olfactory dysfunction, rising prevalence of smell and taste disorders, and increasing incidence of olfactory disorders. Major trends during this period include advancements in intranasal delivery systems, development of neurostimulation-based treatment methods, innovation in smell restoration implants, emerging microbiome-targeted olfactory therapies, and progress in stem cell-derived sensory neuron applications.

The increasing incidence of neurological disorders is expected to propel the growth of the chronic smell and flavor loss treatment market going forward. Neurological disorders are medical conditions affecting the brain, spinal cord, or nerves, often causing muscle weakness, coordination problems, seizures, or changes in behavior and cognition. The rise in these disorders is primarily driven by an aging population, as older individuals are more prone to conditions such as Alzheimer’s disease, Parkinson’s disease, and stroke. Chronic smell and flavor loss treatments support neurological care by addressing sensory deficits, which can be early indicators or consequences of neurodegenerative conditions, facilitating timely diagnosis and improved patient outcomes. For instance, in March 2023, the Alzheimer’s Association, a US-based nonprofit, reported that approximately 6.7 million Americans aged 65 and older were living with Alzheimer’s dementia, with projections rising to 13.8 million by 2060. Therefore, the increasing incidence of neurological disorders is driving the growth of the chronic smell and flavor loss treatment market.

Key companies in the market are focusing on innovative therapies such as intranasal therapeutics to stimulate olfactory nerve regeneration and restore smell function. Intranasal therapeutics are delivered through the nasal passages to promote olfactory nerve function, reduce inflammation, and enhance smell recovery in patients with olfactory disorders. For example, in February 2025, Cyrano Therapeutics, Inc., a US-based clinical-stage regenerative medicine company, launched an investigator-initiated clinical study of CYR-064, its intranasal formulation of theophylline, a broad-spectrum phosphodiesterase (PDE) inhibitor. The formulation aims to increase olfactory neuron excitability and potentially restore the sense of smell, using a soft-mist spray system that ensures precise deposition in the olfactory region for enhanced efficacy and patient comfort.

In November 2023, Fifth Sense Naturals Private Limited, a UK-based charity, partnered with ENT UK to improve care for individuals with smell and taste disorders. This collaboration focuses on professional education, research, expansion of specialist services, and promotion of routine smell testing in clinical practice. ENT UK is a professional membership body representing ear, nose, and throat (ENT) and head and neck surgeons in the United Kingdom.

Major players in the chronic smell and flavor loss treatment market are Pfizer Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Viatris Inc, Hetero Labs Ltd, Sun Pharmaceutical Industries Limited., Aurobindo Pharma Limited., Cipla Ltd., Hikma Pharmaceuticals PLC, Lupin Limited., Zydus Lifesciences Ltd., Alkem Laboratories Ltd, Alembic Pharmaceuticals Limited, Granules India Ltd, Strides Pharma Science Limited, Boys Town National Research Hospital, Tris Pharma Inc., Monell Chemical Senses Center, and Cyrano Therapeutics Incorporated.

North America was the largest region in the chronic smell and flavor loss treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in chronic smell and flavor loss treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the chronic smell and flavor loss treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Chronic smell and flavor loss treatment refers to medical and therapeutic interventions aimed at managing long-term impairments in the senses of smell (olfaction) and taste (gustation). These treatments focus on restoring sensory function, alleviating associated symptoms, and improving quality of life for individuals experiencing conditions such as anosmia, hyposmia, ageusia, or dysgeusia.

The primary types of chronic smell and flavor loss treatment include smell disorder therapeutics and taste disorder therapeutics. Smell disorder therapeutics involve interventions to restore or improve olfactory function in individuals with dysfunctions like anosmia, hyposmia, or parosmia. Treatments include pharmacological therapies, nutritional supplements, cognitive behavioral therapy, olfactory training, and alternative therapies. These address symptoms such as anosmia, hyposmia, dysgeusia, and ageusia. They are administered via oral, nasal, inhalation, or topical routes and serve end users including hospitals, home care settings, and ambulatory surgical centers.

The chronic smell and flavor loss treatment market research report is one of a series of new reports that provides chronic smell and flavor loss treatment market statistics, including chronic smell and flavor loss treatment industry global market size, regional shares, competitors with a chronic smell and flavor loss treatment market share, detailed chronic smell and flavor loss treatment market segments, market trends and opportunities, and any further data you may need to thrive in the chronic smell and flavor loss treatment industry. This chronic smell and flavor loss treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chronic smell and flavor loss treatment market consists of revenues earned by entities by providing services such as olfactory training therapy services, pharmacological treatment services, cognitive behavioral therapy services, nutritional and dietary counseling services, and diagnostic and sensory testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic smell and flavor loss treatment market also includes sales of intranasal corticosteroid sprays, zinc gluconate, olfactory training kits, salivary stimulant tablets, and alpha-lipoic acid capsules. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.